Claims
- 1. A benzothiazole compound represented by the following formula (I): ##STR69## wherein R.sup.1 represents a hydrogen atom, a lower alkyl group or a lower alkoxy group, R.sup.3 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a group represented by the formula: ##STR70## wherein q is an integer of from 1 to 4, or a group represented by the formula: ##STR71## wherein R.sup.7 represents a lower alkyl group; R.sup.4 represents a hydrogen atom, a lower alkyl group, a phenyl group, a group represented by the formula: ##STR72## wherein q is an integer of from 1 to 4, or a group represented by the formula: ##STR73## wherein R.sup.7 represents a lower alkyl group; and one of R.sup.3 or R.sup.4 is either ##STR74## R.sup.2 represents a hydrogen atom or a protective group of a hydroxyl group; and
- R.sup.5 and R.sup.6 are either same or different and each represents a hydrogen atom, a lower alkyl group, an acyl group or a group represented by the formula: ##STR75## wherein r is an integer of from 1 to 4; wherein when R.sup.4 is ##STR76## then at least one of R.sup.5 and R.sup.6 is ##STR77## or an acyl group, or a pharmacologically acceptable salt thereof.
- 2. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.1 is a lower alkyl group.
- 3. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.3 is a group represented by the formula: ##STR78## wherein g is an integer of from 1 to 4.
- 4. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.4 is a group represented by the formula: ##STR79## wherein q is an integer of from 1 to 4.
- 5. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.2 is a hydrogen atom.
- 6. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein one of R.sup.5 and R.sup.6 is a hydrogen atom while the other is a lower alkyl group.
- 7. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein one of R.sup.5 and R.sup.6 is a hydrogen atom while the other is a group represented by the following formula: ##STR80## wherein r is an integer of from 1 to 4.
- 8. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.1, R.sup.4 and R.sup.5 are each a lower alkyl group, R.sup.3 is a group represented by the formula: ##STR81## wherein p is an integer of from 1 to 4; and R.sup.2 and R.sup.6 are each a hydrogen atom.
- 9. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 8, wherein R.sup.3 is a 3-pyridylmethyl group.
- 10. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 8, wherein R.sup.1 and R.sup.4 are each a methyl group. R.sup.2 and R.sup.6 are each a hydrogen atom, R.sup.3 is a 3-pyridylmethyl group and R.sup.5 is an ethyl group.
- 11. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein the benzothiazole derivative is 2-Ethylamino-6-hydroxy-4, 7-dimethyl-5-(3-pyridylmethyl)benzothiazole.
- 12. A pharmacological composition which comprises a therapeutically effective amount of the benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1 and a pharmacologically acceptable vehicle.
- 13. A method for treating a disease in which 5-lipoxygenase activity is raised, comprising administering a pharmaceutically effective amount of the benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1 to a patient suffering from said disease in which the activity of the 5-lipoxygenase is raised.
- 14. A method for treating a disease in which thromboxane synthetase activity is raised; comprising administering a pharmaceutically effective amount of the benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1 to a patient suffering from said disease in which the activity of thromboxane synthetase is raised.
- 15. A method for treating a disease in which leukotriene synthesis is raised, comprising administering a pharmaceutically effective amount of the benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1 to a patient suffering from said disease in which the synthesis of leukotrienes is raised.
- 16. A method for treating a disease in which synthesis of thromboxanes is raised, comprising administering a pharmaceutically effective amount of the benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1 to a patient suffering from said disease in which the synthesis of thromboxanes is raised.
- 17. A method for treating inflammatory bowel diseases, comprising administering a pharmaceutically effective amount of the benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1 to a patient suffering from said inflammatory bowel diseases.
- 18. A method for treating ulcerative colitis, comprising administering a pharmaceutically effective amount of the benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1 to a patient suffering from said ulcerative colitis.
- 19. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.4 is ##STR82## and at least one of R.sup.5 and R.sup.6 is ##STR83## or an acyl group.
- 20. The benzothiazole compound or a pharmacologically acceptable salt thereof as claimed in claim 1 of the formula ##STR84##
Priority Claims (2)
Number |
Date |
Country |
Kind |
3-071480 |
Apr 1991 |
JPX |
|
3-281366 |
Oct 1991 |
JPX |
|
Parent Case Info
This application is a divisional of copending application Ser. No. 08/148,914, filed on Nov. 5, 1993, now U.S. Pat. No. 5,420,144 which is a divisional application of Ser. No. 07/861,379, filed on Mar. 31, 1992, now U.S. Pat. No. 5,300,518, the entire contents of which are hereby incorporated by reference.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
1931077 |
Lubs et al. |
Oct 1933 |
|
4763346 |
Anderson |
Aug 1988 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
0295656 |
Dec 1988 |
EPX |
0356234 |
Feb 1990 |
EPX |
156830 |
Dec 1969 |
HUX |
Non-Patent Literature Citations (4)
Entry |
Chemical Abstracts, vol. 98. No. 23, Abstract No. 198,090u, Jun. 6, 1983, pp. 641-662. |
Srivastava et al, J. Med. Chem, vol. 13, No. 5, 1970, pp. 977-979. |
Journal of Organic Chemistry, vol. 35, No. 12, (1970) pp. 4103-4108 P.T.S. Lau et al. |
Journal of Medicinal Chemistry, vol. 25, No. 6, (1983), pp. 654-657 European Search Report (2). |
Divisions (2)
|
Number |
Date |
Country |
Parent |
148914 |
Nov 1993 |
|
Parent |
861379 |
Mar 1992 |
|